Axicabtagene ciloleucel for the treatment of relapsed or refractory follicular lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Expert Review of Anticancer Therapy"
DOI: 10.1080/14737140.2022.2096009
Abstract: ABSTRACT Introduction Axicabtagene ciloleucel is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy that was recently approved for relapsed or refractory follicular lymphoma following progression on two or more lines of therapy including an… read more here.
Keywords: axicabtagene; relapsed refractory; follicular lymphoma; axicabtagene ciloleucel ... See more keywords
Chimeric antigen receptor (CAR) T-cell therapy as a treatment option for patients with B-cell lymphomas: perspectives on the therapeutic potential of Axicabtagene ciloleucel
Sign Up to like & getrecommendations! Published in 2019 at "Cancer Management and Research"
DOI: 10.2147/cmar.s163225
Abstract: Abstract Axicabtagene lisoleucel (Axi-cel) is the second approved gene-alterating cancer treatment and the first in aggressive lymphoma using the “chimeric antigen receptor” (CAR) technology. T-cells from patients were transfected with CARs and reinfused after a… read more here.
Keywords: receptor car; axicabtagene; treatment; antigen receptor ... See more keywords